What is it about?
NAC is recommended by multiple guidelines in treatment o MIBC. Recommendation are mainly based on different chemotherapy regimens. Cis-gem has been used in metastatic patients. We report national tolerability results with over 200 patients treated in NAC setting.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Cis-gem has been shown similar efficacy to MVAC with better tolerability profile in metastatic MB patients. Despite the regimen has been used for a decade in Finland, thorough evaluation has been lacking. Our objective was to evaluate tolerability of cis-gem NAC treatment and identify potential risk factors for poor tolerance.
Perspectives
I had the privilege to gather national data of NAC treatment. Together with my co-authors we are pleased to report the Finnish experience. Work continues in National data gathering.
Antti Salminen
Turku University Hospital Finland
Read the Original
This page is a summary of: Adverse Events During Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer, Bladder Cancer, December 2019, IOS Press,
DOI: 10.3233/blc-190246.
You can read the full text:
Contributors
The following have contributed to this page
